On the afternoon of March 17, Shi Yuanyuan, chairman of our company, was invited to attend Shenzhen BioPark& Xingyzsj.neti lecture - "New Drug Development Strategy under ICH Environment".

At the roundtable forum, Chairman Professor Shi Yuanyuan, foreign academician Zhang Dan of the Russian Academy of Engineering, Chairman Meng Fanqiang of Hanbo Ruiqiang (Shanghai) Pharmaceutical Technology Co., LTD., Chairman Liu Feng of Guangzhou Diqi Pharmaceutical Technology Co., LTD., co-founder and Vice President Li Tianquan, Jin Feng, director of R&D Department of Guangdong Small Molecule New Drug Innovation Center and deputy general manager of Xinyue Biology, and many other experts discussed the theme of "Product strategy of Chinese pharmaceutical companies in the ICH Era" and conducted an in-depth analysis of new drug research and development under the background of ICH.


Experts agree that Chinese pharmaceutical companies need to have a global vision and global ambitions. Professor Shi Yuanyuan especially pointed out that for the emerging third generation of cell and gene therapy drugs, developers need to maintain international communication more, because the technology in this field is changing rapidly, and mentioned that in 2022, six CAR T products will be launched globally. Combined sales of the two retroviral vector based CAR-T drugs (both from Gilead) reached $1.46 billion, while the four lentiviral vector based CAR-T drugs (each from Novartis, Bristol-Myers Squibb and Johnson & Johnson Legend) combined sales of $1.24 billion. Thanks to the low industrial production cost and high production capacity, the use of retroviral vectors to develop cell therapy drugs has formed a new trend in the world, while in the domestic cell therapy industry is still relatively unfamiliar with this technology, which requires high attention.